{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:08:45Z","timestamp":1790737725178,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bbrc.2018.11.035","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T01:37:10Z","timestamp":1542159430000},"page":"330-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Interferon-\u03b2 signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells"],"prefix":"10.1016","volume":"507","author":[{"given":"Yoshie","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunao","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-3556","authenticated-orcid":false,"given":"Osam","family":"Mazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.11.035_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2018.11.035_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","article-title":"Mechanisms of immune evasion by tumors","volume":"90","author":"Drake","year":"2006","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2018.11.035_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T\u00a0cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2018.11.035_bib9","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2018.11.035_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signature of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2018.11.035_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7-H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I IFN response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"Bon","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2018.11.035_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2005.25.733","article-title":"Stats: multifaceted regulators of transcription","volume":"25","author":"Brierley","year":"2005","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2017.05.059","article-title":"Efficient direct conversion of human fibroblasts into myogenic lineage induced by co-transduction with MYCL and MYOD1","volume":"488","author":"Wakao","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2018.11.035_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bbrc.2005.02.088","article-title":"Intracellular interferon triggers Jak\/Stat signaling cascade and induces p53-dependent antiviral protection","volume":"329","author":"Shin-ya","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2018.11.035_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/2326-6066.CIR-17-0150","article-title":"Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC","volume":"5","author":"Brockwell","year":"2017","journal-title":"Canc. Immunol. Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407899","article-title":"Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade","volume":"7","author":"Waele","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbrc.2018.11.035_bib26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1078-0432.CCR-13-2781","article-title":"Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors","volume":"20","author":"Nagato","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2556","article-title":"Garden of therapeutic delights: new targets in rheumatic diseases","volume":"11","author":"Waldburger","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbrc.2018.11.035_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Panes","year":"2018","journal-title":"J.\u00a0Crohns Colitis."},{"key":"10.1016\/j.bbrc.2018.11.035_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.11.035_bib31","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/jog.13411","article-title":"Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status","volume":"43","author":"Yang","year":"2017","journal-title":"J.\u00a0Obstet. Gynaecol. Res."},{"key":"10.1016\/j.bbrc.2018.11.035_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CJI.0000000000000187","article-title":"Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma","volume":"40","author":"Huang","year":"2017","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.bbrc.2018.11.035_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminoncol.2014.02.002","article-title":"Interferons and their stimulated genes in the tumor microenvironment","volume":"41","author":"Cheon","year":"2014","journal-title":"Semin. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18324410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18324410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:29:12Z","timestamp":1757762952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X18324410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"1-4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0006291X18324410"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.035","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b2 signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}